Harbor Capital Advisors Inc. Acquires 2,064 Shares of Health Catalyst, Inc. (NASDAQ:HCAT)

Harbor Capital Advisors Inc. boosted its holdings in Health Catalyst, Inc. (NASDAQ:HCAT) by 21.3% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,764 shares of the company’s stock after buying an additional 2,064 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in Health Catalyst were worth $96,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of HCAT. Nisa Investment Advisors LLC lifted its holdings in shares of Health Catalyst by 461.0% in the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after acquiring an additional 5,232 shares during the last quarter. Quarry LP grew its holdings in shares of Health Catalyst by 59.4% during the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after purchasing an additional 2,610 shares during the last quarter. nVerses Capital LLC acquired a new position in Health Catalyst during the 3rd quarter worth approximately $59,000. Perfromance Wealth Partners LLC bought a new position in Health Catalyst in the 2nd quarter valued at approximately $64,000. Finally, Mackenzie Financial Corp acquired a new stake in Health Catalyst in the second quarter valued at approximately $70,000. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Stock Performance

NASDAQ:HCAT opened at $8.24 on Friday. Health Catalyst, Inc. has a 52 week low of $5.42 and a 52 week high of $11.41. The firm’s fifty day moving average is $8.07 and its 200-day moving average is $7.14. The firm has a market cap of $498.27 million, a P/E ratio of -5.49 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.04. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. The business had revenue of $75.90 million for the quarter, compared to analysts’ expectations of $74.96 million. During the same quarter in the prior year, the firm posted ($0.21) earnings per share. The business’s quarterly revenue was up 3.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that Health Catalyst, Inc. will post -0.35 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on HCAT shares. Evercore ISI upped their price target on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Royal Bank of Canada upped their target price on Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a report on Thursday. Piper Sandler reduced their price target on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a report on Monday, August 26th. Stephens lowered their price objective on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a research note on Thursday, August 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a research report on Friday, October 4th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $11.64.

Insider Activity

In related news, COO Daniel Lesueur sold 8,137 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total transaction of $61,678.46. Following the transaction, the chief operating officer now owns 140,108 shares in the company, valued at $1,062,018.64. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Health Catalyst news, COO Daniel Lesueur sold 8,137 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total transaction of $61,678.46. Following the completion of the sale, the chief operating officer now owns 140,108 shares in the company, valued at approximately $1,062,018.64. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the transaction, the insider now directly owns 255,881 shares in the company, valued at $1,847,460.82. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 35,396 shares of company stock valued at $266,280 in the last ninety days. 2.50% of the stock is owned by company insiders.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.